Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions

$149m La Jolla Purchase Expands Hospital Presence

 
• By Mandy Jackson

Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.

Merging; two merchants push one red square and three white squares together
Innoviva hopes to add a future Entasis product into La Jolla's commercial portfolio • Source: Shutterstock

More from Deals

More from Business